

The ECMC Initiative (2007-2016) Adult and Paediatric ECMC Networks

Bringing faster and better treatments to cancer patients in the UK












NHS National Institute for Health Research

Ten years of the ECMC initiative





What I will cover today

- A look back at the changes the last ten years have brought
- Highlight a few of the fantastic things we have delivered as a Network
- Some thoughts about the future challenges for the Network
- Some reflections on how well the Network is positioned to meet these challenges



Still a funding partnership










Still a funding partnership



Still a funding partnership r&d office **CANCER RESEARCH UK SCIENTIS** Department OFFICE Llywodraeth Cynulliad Cymru of Health Welsh Assembly Government CANCER Ymchwil lechyd CHIEF NHS HSC a Gofal Cymru RESEARCH **S**CIENTIST National Institute for Health and Care OFFICE IJК Health Research Research Wales

Still a partnership between the NHS and academia





The Newcastle upon Tyne Hospitals NHS Foundation Trust

















Still UK Wide






Huge changes in the research landscape





CLINICAL RESEARCH NETWORK

Our understanding of cancer has also changed

Cancer now has 10 hallmarks








Cancer evolves

Tumours are heterogenous




the ONION

Latest Study Finds Cancer Cells Now Cruelly Mocking Researchers

NEWS October 23, 2012 VOL 48 ISSUE 43 Science & Technology






Scientists say cancer cells like this are just laughing in their goddamned faces.

Man On Rolling Away From Des Breaking Forma

We are making a difference



Based on children aged 14 or under surviving cancer for 10 years or more.



Unique Kinetics of Response in Patients Treated With Ipilimumab

and Progression

Week 12: Swelling





Week 16: Continued Improvement

Week 72: Complete Remission



Week 12: Improved



Funding partners perspective

"The ECMC Network has been hugely successful. It will continue to play a key role in delivery against the strategic objectives of all the funders, including driving faster translation of scientific discoveries into tangible benefits for patients, increasing the attractiveness of the UK to industry, making precision cancer medicine a reality, and providing patients access to clinical studies"








The Experimental Cancer Medicine Centre Initiative is jointly funded by Cancer Research UK, the National Institute for Health Research in England and the Health Departments for Scotland, Wales and Northern Ireland.

Delivering against objectives





Objective 1: Innovative treatments



Over **1,500** new early phase clinical trials

Over **18,000** patients recruited

35 cancer types

Over £155m leveraged from industry

Paediatric Network Successes


With 9 sites in England and Scotland, the Paediatric ECMC Network has successfully managed a wide portfolio of early phase academic and commercial studies.

INTERNATIONAL RECOGNITION:

- 5 ECMCs have accreditation from the Innovative Therapies for Children with Cancer (ITCC)
- Open door to commercial EU trials such as E-SMART (ITCC initiative) - Ph I/II basket study matching small molecules to genomic profile that involves several pharma companies.

COLLABORATION WITH NATIONAL INITIATIVES:

- The national functional imaging network for childhood cancer has recruited >1000 pt across 10 centres (inc. 6 ECMCs).
- Before the ECMC Network 60 patients/year after 100 patients/year.
- The ECMC Network has helped incorporating these studies into clinical practice, particularly for **brain tumours**.



ECMC Combinations Alliance





BIOTHERA the immune health company





MedImmune

- 9 new commercial partners
- 180+ expressions of interest
- 1 or more proposed from each ECMC
- 21 trials with 381 patients treated
- 2 cross-company studies with 5 radiotherapy combinations
- 1st paediatric trial with adults in parallel









Precision Medicine across the ECMC Network

CRUK's Stratified Medicine Programme 2


- Recruiting at 16/18 ECMCs
- Network spans more than 40 NHS trusts
- Over 1000 patients have had their sample tested by NGS at 1 of 3 Technology Hubs
- Of these, more than **400** samples are molecularly eligible for MATRIX
- A 3.7% conversion rate to MATRIX

Birmingham CRCTU's National Lung Matrix Trial

- Trial opened in March 2015
- Open at 11 ECMCs
- There are **54** patients receiving targeted therapy
- The 50th patient recruited on 1 year anniversary of trial opening
- Amendment review to include 2 new arms and extend 1 cohort



Delivering against objectives





Objective 2: Improving competitiveness

- Influencing regulation at a national level to benefit the Network
 - HRA Approval
 - Single Technical Pharmacy review
 - Medical exposure review
 - Devolved nations co-ordination
- Developing agreements to facilitate working with the Network
 - Joint NDA, MTA, Collaboration Agreement, Operational Guidelines
- Facilitating industry access to the Network
 - Coordinated Network-wide Expression of Interest (EoI) process
 - Facilitation of feasibility/site selection processes with commercial sponsors
- In this quinquennium 63% of new studies reported are commercial trials



The Network leading the way

- The ECMC Network has led the way in several important areas
 - Networking: the Network is the oldest in Europe
 - Trial Harmonisation: processes developed in the Network now being implemented for all studies using HRA approval
 - Stratified medicine: the Network is delivering challenging studies nation wide, and other indications are learning from us how to do this



Delivery against objectives



Objective 1

Innovative treatments for cancer patients Make the UK a competitive place to perform experimental cancer medicine **Objective 3**

Build the UK's capacity (staff & infrastructure) in experimental cancer medicine



Objective 3: Building Capacity (Network Groups)

- Cellular and Molecular Pathology (CMP) Network Group
- CRUK, ECMC and UK Radiopharmacy Group Taskforce (CERT)
- Junior Investigators Network Group (JING)
- Patient and Public Involvement Group (PPI)
- Quality Assurance and Translational Science (QATS) Network Group
- Research Nurses Network Group
- UK Therapeutic Cancer Prevention Network Group (UKTCPN)



Annual events

JING –Training the Next Generation Newcastle 2016





What were the most valuable elements Of the residential?



How would you describe JING TNG?

Research Nurses – An introduction to early phase cancer trials training day

For research nurses working in early phase cancer research for 3-12 months.



ECMC Research Nurse Network Group An introduction to early phase cancer trials: everything you wanted to know but were too afraid to ask Monday 29 February 2016 9:30am-4pm The Studio 7 Cancer Street Reministram 82 SEP

> Registration is **OPEN** Places are limited - please register early by email to hannah.brown@cancer.org.uk

hannah.brown@cancer.org.uk

cancer traits:everything you wanted to know but were too afraid to ask a second day is being run. The aim of this course is to equip new early phase nurses to deliver high quality patient-centred care, within the clinical trait regulatory framework. This course is primarily aimed at research nurses who have been working in

This course is primarily aimed at research nurses who have been working in early phase cancer research between 3 and 12 months. This is also a great opportunity to meet other research nurses who are new

This is also a great opportunity to meet other research nurses who are ne to early phase trials and gain support from those in the Beld



Attendee at the pilot study day

66Considering a move into

Phase I and now feel more conident and excited This training day is due to be run again in September 2017

"[It was] good to share problems and experiences and to discuss difficulties experienced by staff involved in Phase I trials"

Raising the profile of the Network



Website External portal to the Networks with 10,000 page views a month

Twitter @ECMC UK >1,100 followers



SPOTLIGHT: Prostate and Ovarian cancer awareness month

Lorraine Turner wins Oncology Nurse of the Year [more]

Newsletter 14 🎔

April 2016

"Patients are the true pioneers of cancer medicine' - Dr Udai Banerii, ICR

Science News

STREE DADS

- New VAPER trial to test cancer-killing vaccine King's study administers vaccine in first patient [more]
- Drug could help immune system fight cancer Southampton running AMG319 phase-II trial [more]
- microRNA-224 colorectal cancer study miRNA224 associated with cancer progression and response to treatment [more]
- Neonates study collaboration between ECMC Networks Collaboration leads to possible gold standard treatment for neonates with retinoblastoma [more]

Centre for Drug

Development CDD are to host antimetastatic workshop at ECMC's Annual Network Meeting, with Prof Jeff Evans [more]

Stratified Medicine Programme Update on the National Lung Matrix Trial, a flagship precision medicine trial, supported by SMP-Phase 2 screening platform [more]

Combinations Alliance CTRad and Combinations Alliance organised a Radiotherapy-Immunotherapy workshop, led by Dr Adams and Prof

May 11: Informed consent [more] May 19: Patient involvement in research Twitter chat [more] May 25: Applying for ethical opinion in the NHS [more] May 31: Deadline for JING Bursary to attend CSGs Trainee Scheme [more] June 1: NRS introduction to good clinical practice -

Newsletter Sent to >1,100 Network members





as s provinci é first in combination.

across our Network. Read more.

During March, we ran a Twitter campaian to raise awareness of these cancer types, featuring

prostate and ovarian trials from

In this issue:

Interview: Dr Karin Oien



Path. [more]

Training Courses & Schemes

Glasgow [more]



Future challenges

- Working with industry
 - Need to unequivocably demonstrate UK ability to deliver
- Trial delivery challenges have shifted
 - Set up is now less challenging, dealing with SAEs and SUSARs now a major time drain
- Complex studies need appropriate supporting infrastructure over multiple sites
 - e.g. Pathology, lab services, imaging, informatics, regulatory
- Complex studies are challenging for patients and physicians
 - Multiple / repeat biopsies
 - Possibly multiple trial choices
- The Network needs to adapt and be responsive to changes in the science
 - Changes in regulation are sluggish e.g. consent

Some changes are in progress



 Focus on therapies – early phase interventional trials and associated translational research



 Managed Network – creation of a Central Programme Office and Collaboration Agreement



• New governance – greater responsibility for the Network in the Network



Collaboration Agreement



The ECMC Initiative 2007-2016

- () 1 Goal
- **2** Networks
- ℓ 5 Funders
- ℓ 20 sites
- **£70m investment**
- € 35 cancer types
- </p
- ℓ >18,000 patients recruited



"Approaching 10 years of *CECMC* collaboration"

Thank you!







Ymchwil lechyd a Gofal <mark>Cymru</mark> Health and Care Research <mark>Wales</mark>



NHS National Institute for Health Research